Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.
Type:
Grant
Filed:
August 31, 2011
Date of Patent:
May 14, 2013
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A synthetic gene devoid of CpG nucleotide derived by genetic engineering from copepod luciferases genes that code for a new secreted luciferase with a strong bioluminescent signal. This gene display advantageous properties to be used as a reporter genes in cell based assays.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
May 7, 2013
Assignee:
Cayla
Inventors:
Jean Paul Reynes, Céline Casteran, Daniel Drocourt, Gérard Tiraby
Abstract: The present invention pertains in general to Bromelain and particularly to the different active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed cysteine proteases, which are found in Bromelain. It has been found that the method for expression of the recombinant proteins is superior to the purification from Bromelain itself.
Type:
Grant
Filed:
August 8, 2008
Date of Patent:
April 2, 2013
Assignee:
Ursapharm Arzneimittel GmbH
Inventors:
Rolf Müller, Nora Luniak, Klaus Eschmann
Abstract: It is an object of the present invention to provide: a protein refolding column filler, which is effective for the refolding, namely, the activation of the function, of an inactive protein with an as yet unformed higher order structure produced in Escherichia coli or the like, or a protein whose conformation has been changed due to a certain cause and which has become inactivated; and a column filled with the aforementioned column filler. The present invention provides a protein refolding column filler, which comprises zeolite with BEA structure (Zeolite Beta) that is granulated into a particle state.
Abstract: The present invention relates to a recombinant organism having any one of nucleic acids (i) to (iv) introduced therein: (i) a nucleic acid having a base sequence of SEQ ID NO: 1; (ii) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2; (iii) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (i); (iv) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (i) under stringent conditions.
Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
Type:
Grant
Filed:
April 13, 2009
Date of Patent:
March 12, 2013
Assignee:
The Regents of the University of Michigan
Inventors:
David Ginsburg, Gallia Levy, Han-Mou Tsai
Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.
Type:
Grant
Filed:
February 11, 2011
Date of Patent:
March 5, 2013
Assignee:
Lantmannen AS-Faktor AB
Inventors:
Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
Abstract: The present invention relates to subtilase subtilases with an altered immunogenicity, particularly subtilases with a reduced allergenicity. Furthermore, the invention relates to expression of said subtilase variants and subtilases and to their use, such as in detergents and oral care products.
Abstract: The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN? subtilase and to TY145 and BPN? variants having altered properties as compared to the parent TY145/BPN? subtilase.
Abstract: Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta-9 elongases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) and using these delta-9 elongases in plants.
Abstract: The invention relates to a novel 3D structure encoding a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.
Type:
Grant
Filed:
January 5, 2011
Date of Patent:
February 19, 2013
Assignee:
Novozymes A/S
Inventors:
Leonardo De Maria, Carsten Andersen, Lars Lehmann Hylling Christensen, Soren Flensted Lassen, Peter Rahbek Ostergaard
Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
Type:
Grant
Filed:
October 24, 2008
Date of Patent:
February 12, 2013
Assignee:
MannKind Corporation
Inventors:
Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
Abstract: A hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, it produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The fibrin components are produced by a novel dialysis method which does not present thrombin to the immune system and can be maintained in solution for six weeks without significant proteolytic degradation.
Abstract: A repetitive protein having repetition units comprising the consensus sequence (I) X1?X2?X3?X4?S?X5?X6?Y?G wherein X1 is G, Y, A or N X2 is G, L, Q X3 is R, K, T or P X4 is P, A, T or S X5 is D, T or S X6 is S, Q or T, and the consensus sequence (II) Z1?Z2?(Z3A)nZ4?Z5?Z6 wherein Z1 is S, Q, N, T or G Z2 is not an amino acid or A Z3 is A or G Z4 is not an amino acid, A or S Z5 is G, S, Q, N or T Z6 is G, P, S, Q, N or T n is a natural whole number, wherein 2?n?12.
Type:
Grant
Filed:
June 16, 2008
Date of Patent:
February 5, 2013
Assignee:
BASF SE
Inventors:
Burghard Liebmann, Marcus Fehr, Daniel Hümmerich
Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.
Type:
Grant
Filed:
July 30, 2012
Date of Patent:
January 22, 2013
Assignee:
Danisco US Inc.
Inventors:
John Bryan Jones, Michael Dickman, Richard C. Lloyd
Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.
Type:
Grant
Filed:
September 20, 2011
Date of Patent:
January 15, 2013
Assignee:
Battelle Energy Alliance, LLC
Inventors:
David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
Abstract: Process for extracting hydrophobin from a solution wherein carrageenan is added to the solution and the pH of the solution is brought below 3.5, and the ionic strength of the solution is below 0.5.
Abstract: A method of producing hexose oxidase by recombinant DNA technology, recombinant hexose oxidase and the use of such enzyme, in particular in the manufacturing of food products such as doughs and dairy products, animal feed, pharmaceuticals, cosmetics, dental care products and in the manufacturing of lactones. Suitable sources of DNA coding for the enzyme are marine algal species including Chondrus crispus, Iridophycus flaccidum and Euthora cristata. In useful embodiments, the recombinant hexose oxidase is produced by Pichia pastoris, Saccharomyces cerevisiae or E. coli.
Abstract: The efficiency of production of a heterologous protein by a transformant of a yeast host is improved. A method of constructing a host for expression of a foreign gene which comprises deleting or inactivating at least one gene selected from the protease-associated genes (especially, metalloprotease genes and serine protease genes) of Schizosaccharomyces pombe, a host in which the above-mentioned gene is deleted or inactivated, a transformant obtained by introducing a foreign gene into the host and a method of producing a heterologous protein using the transformant. The protease-associated gene is at least one gene selected from the group consisting of psp3 (SPAC1006.01), is sxa2 (SPAC1296.03c), ppp51 (SPAC22G7.01c) and ppp52 (SPBC18A7.01) or at least two genes selected from the group consisting of metalloprotease genes and serine protease genes, especially, three genes psp3 (SPAC1006.01), isp6 (SPAC4A8.04) and ppp53 (SPAP14E8.04).